CN105566329A - 一种吡唑[5，6-d]并嘧啶类EGFR抑制剂及其抗肿瘤活性 - Google Patents
一种吡唑[5，6-d]并嘧啶类EGFR抑制剂及其抗肿瘤活性 Download PDFInfo
- Publication number
- CN105566329A CN105566329A CN201410635578.4A CN201410635578A CN105566329A CN 105566329 A CN105566329 A CN 105566329A CN 201410635578 A CN201410635578 A CN 201410635578A CN 105566329 A CN105566329 A CN 105566329A
- Authority
- CN
- China
- Prior art keywords
- cancer
- egfr
- compound
- tumor
- related diseases
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000000259 anti-tumor effect Effects 0.000 title abstract description 10
- 229940121647 egfr inhibitor Drugs 0.000 title abstract description 9
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 title description 4
- 150000001875 compounds Chemical class 0.000 claims abstract description 33
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 14
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 9
- 201000005202 lung cancer Diseases 0.000 claims description 9
- 208000020816 lung neoplasm Diseases 0.000 claims description 9
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 8
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- PZURVUQVDFSJJO-UHFFFAOYSA-N pyrimidine-4,6-diamine Chemical compound NC1=CC(N)=N[C]=N1 PZURVUQVDFSJJO-UHFFFAOYSA-N 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 206010006187 Breast cancer Diseases 0.000 claims 5
- 208000026310 Breast neoplasm Diseases 0.000 claims 5
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 claims 2
- 102000001301 EGF receptor Human genes 0.000 claims 2
- 108060006698 EGF receptor Proteins 0.000 claims 2
- 239000007788 liquid Substances 0.000 claims 2
- 206010004593 Bile duct cancer Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 208000032271 Malignant tumor of penis Diseases 0.000 claims 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000002471 Penile Neoplasms Diseases 0.000 claims 1
- 206010034299 Penile cancer Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 206010046798 Uterine leiomyoma Diseases 0.000 claims 1
- 208000026900 bile duct neoplasm Diseases 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000010260 leiomyoma Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 206010027191 meningioma Diseases 0.000 claims 1
- 239000002674 ointment Substances 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 abstract description 6
- -1 pyrimidine compound Chemical class 0.000 abstract description 5
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 25
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 25
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 23
- 108091000080 Phosphotransferase Proteins 0.000 description 21
- 102000020233 phosphotransferase Human genes 0.000 description 21
- 230000002401 inhibitory effect Effects 0.000 description 12
- 230000000694 effects Effects 0.000 description 9
- 206010059866 Drug resistance Diseases 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 230000026731 phosphorylation Effects 0.000 description 4
- 238000006366 phosphorylation reaction Methods 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 230000019491 signal transduction Effects 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 239000011535 reaction buffer Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- IEQAICDLOKRSRL-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO IEQAICDLOKRSRL-UHFFFAOYSA-N 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 2
- ULXXDDBFHOBEHA-CWDCEQMOSA-N afatinib Chemical compound N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-CWDCEQMOSA-N 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 102100023593 Fibroblast growth factor receptor 1 Human genes 0.000 description 1
- 101710182386 Fibroblast growth factor receptor 1 Proteins 0.000 description 1
- 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 description 1
- 101000851018 Homo sapiens Vascular endothelial growth factor receptor 1 Proteins 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- 206010023774 Large cell lung cancer Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 229960001686 afatinib Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 230000007783 downstream signaling Effects 0.000 description 1
- 229960001433 erlotinib Drugs 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
- 231100000086 high toxicity Toxicity 0.000 description 1
- QQLKULDARVNMAL-UHFFFAOYSA-N icotinib Chemical compound C#CC1=CC=CC(NC=2C3=CC=4OCCOCCOCCOC=4C=C3N=CN=2)=C1 QQLKULDARVNMAL-UHFFFAOYSA-N 0.000 description 1
- 229950007440 icotinib Drugs 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 229940084651 iressa Drugs 0.000 description 1
- 238000000021 kinase assay Methods 0.000 description 1
- 201000009546 lung large cell carcinoma Diseases 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 238000005556 structure-activity relationship Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940120982 tarceva Drugs 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000005747 tumor angiogenesis Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明提供了一种EGFR抑制剂类具有抗肿瘤作用的吡唑[5，6-d]并嘧啶类化合物。另外，本发明还提供了该化合物的药物组合物以及抗肿瘤用途等。
Description
技术领域
本发明属于药物化学领域，具体而言，本发明涉及一种有良好抗肿瘤活性的吡唑[5，6-d]并嘧啶类化合物。另外，本发明还涉及含有该种化合物的药物组合物及其在制备抗肿瘤药物中的用途等。
背景技术
肺癌是发病率和病死率最高的恶性肿瘤之一，在世界范围内每年因肺癌导致的死亡超过100万人；在我国，肺癌的发病率和死亡率在恶性肿瘤中长期居于首位，其中以非小细胞肺癌(NSCLC)最为普遍，占发病总数的85％以上。目前，经典的手术切除或放化疗往往存在术后复发率高、毒副作用大、转移和耐药等多种缺陷。鉴于EGFR信号途径在诱发NSCLC肿瘤生长和血管增生中的重要作用，EGFR已经成为NSCLC靶向治疗的重要靶点，其相应的小分子抑制剂成为各大医药公司争相研发的重要领域。
目前，已有近20种EGFR抑制剂药物进入临床试验阶段或陆续上市。其中，被认为是第一代EGFR抑制剂的易瑞沙(Gefinitib)、特罗凯(Erlotinib)和我国自主研发上市的凯美纳(Icotinib，2012年上市)等已在临床NSCLC病人治疗中获得巨大成功。但经6～12个月的治疗后往往会发生明显的继发性耐药，极大的限制了患者生存时间的延长，目前研究认为这种耐药通常是由于EGFR20号外显子T790M错位突变所引起。2013年，BoehringerIngelheim公司成功开发了首个第二代EGFR抑制剂Afatinib(BIBW2992)，其主要特点是可以显著抑制EGFRT790M，有效逆转T790M所引起的耐药。但是，Afatinib同时也强烈抑制野生型EGFR(EGFRWT)，阻止体内正常组织EGFRWT激酶的磷酸化和相关信号通路的激活，从而带来较大的药物毒副作用，临床上表现为皮疹、呕吐等药物毒副反应。因此，开发具有高特异性EGFRT790M突变体抑制剂已成为研发新一代抑制剂的首要目标。
目前，EGFR抑制剂的构效关系并不明朗，有的结构差别很小的化合物，其针对EGFR抑制的效果却相差很大。本发明人经过艰苦努力，令人意外地设计并合成出一种新的吡唑[5，6-d]并嘧啶类化合物，其具有优良的EGFRT790M抑制效果和选择性，属于第三代EGFR抑制剂，能用于治疗各种EGFRT790M高表达的肿瘤。
发明内容
本发明要解决的技术问题是提供新的EGFR抑制剂类抗肿瘤化合物及其药物。
具体而言，本发明提供了式(WZ00411)所示的化合物或者其药学上可接受的盐：
化合物(WZ00411)为：
N6-(1H-吲哚-5)-N2-(4-(4-氮甲基哌嗪苯基)-1H-吡唑[5，6-d]并嘧啶-4，6-二胺
N4-(1H-indol-5-yl)-N6-[4-(4-methylpiperazin-1-yl)phenyl]-1H-pyrazolo[3，4-d]pyrimidine-4，6-diamine
本发明要解决的技术问题在于提供新的含吲哚的嘧啶[5，6-d]并咪唑类化合物和/或提供其在治疗或预防肿瘤(尤其是EGFR依赖性或EGFRT790M突变高表达类肿瘤)方面的新用途。
本发明的目的之一是提供一种新型的吡唑[5，6-d]并嘧啶类EGFR抑制剂。
本发明的目的之二是提供一种新型的吡唑[5，6-d]并嘧啶类EGFR抑制剂的制备方法及抗肿瘤活性。
在本发明中，我们首先利用化学方法合成了一种新型的吡唑[5，6-d]并嘧啶类化合物WZ00411。利用体外激酶层次上的活性筛选实验证实了化合物WZ00411具有强烈的EGFRT790M抑制活性，同时对EGFRWT具有一定选择性并对其他激酶抑制活性较弱，具备良好的激酶选择性和第三代EGFR抑制剂特点(详情见实施例1)。细胞层面上实验也证实该化合物可以有效抑制EGFR及其下游信号p-Akt和p-Erk的磷酸化水平(详情见实施例2)。
附图说明：
这里所列举的化合物只是为了更好地说明本发明的化合物类别和结构形式，并非限制本发明。
图1说明合成的化合物WZ00411化学结构；
图2说明激酶选择性抑制测试；
图3说明化合物细胞水平上化合物的抗肿瘤活性验证。
图4说明化合物在H1975细胞水平上对下游信号通路蛋白磷酸化抑制作用。
实施例1化合物体外抑制EGFR的活性和选择性
EGFR激酶体外活性筛选：实验采用方法为CaliperMobilityShiftAssay，该方法是以微流体芯片技术的迁移率检测技术为核心的检测平台。实验步骤：配置1.25x激酶反应缓冲液(62.5mmol/LHEPES，pH7.5；0.001875％Brij-35；12.5mmol/LMgCl2；2.5mMDTT)和激酶反应终止液(100mmol/LHEPES，pH7.5；0.015％Brij-35；0.2％CoatingReagent#3)；在5μl的5x浓度的化合物溶液中(用DMSO溶解，用水稀释10倍)加入10μl的2.5x的FGFR1激酶溶液(在1.25x激酶反应缓冲液中加激酶)，室温孵育10min后再加入10μl的2.5x底物肽溶液(在1.25x激酶反应缓冲液中加FAM标记肽和ATP)，在28℃下反应特定的时间后加入25μl激酶反应终止液。在Caliper上测试收集数据，对激酶活性的抑制率＝(max-conversion)/(max-min)*100。“max”为未加化合物的DMSO对照，“min”为低对照。测定IC50时每种样品设10个稀释度各2个复孔，3次重复。
激酶选择性抑制测试：将WZ00411依照上述激酶抑制活性测定方法，测定对VEGFR1、EGFR、PDGFR、FGFR1～2和C-Met等6种常见激酶的抑制活性，同时比较EGFRWT/EGFRT790M激酶IC50活性比值，以表征这些化合物对EGFRWT和其他激酶的选择性。以表征该化合物对激酶的选择性。
激酶实验表明：化合物WZ00411对EGFRWT/EGFRT790M抑制IC50分别为21.33和1156.62nMol。对其它常见5种激酶的抑制活性均大于5000nMol(实验数据见图2)，因此具有良好的EGFRT790M抑制活性和EGFRWT/EGFRT790M及其他激酶选择性。(见图2)
实施例2细胞水平上化合物的抗肿瘤活性验证
采用MTT法化合物WZ00411在细胞层面上的抗肿瘤活性，选用含EGFRT790M高表达的人NSCLC细胞株(H1975)、EGFRWT高表达的人大细胞肺癌细胞株(A549)以及EGFR原发性错位突变的人肺癌细胞株(HCC827)等7种细胞进行增殖抑制活性测试。测定时以PBS为空白对照，EGF为阴性对照，(EGF+WZ4002)为阳性对照，(EGF+待测样品)为实验组，每种样品设6个浓度梯度，计算IC50值。
活性化合物对胞内EGFR促增殖信号通路的影响：选取化合物WZ00411，用EGF联合不同浓度的WZ00411分别处理含EGFRT790M高表达的非小细胞肺癌H1975细胞；提取细胞总蛋白后，经Westernblotting检测细胞内EGF/EGFR信号通路中促增殖信号分子EGFR、ERK和AKT磷酸化水平的变化。
细胞实验表明：化合物WZ00411体现了良好的EGFRWT/EGFRT790M选择性。对EGFRT790M激酶抑制活性均达到20nMol，具有潜在的优化前景，并且拥有比WZ4002更优秀的激酶选择性，化合物WZ00411对EGFRWT/EGFRT790M选择性为55倍(见图3)。此外，WZ00411具有较好的抗肿瘤增殖活性，并在1、10、100和1000nMol四种浓度下均可强烈抑制H1975细胞中p-EGFR，p-AKT和p-ERK水平(见图4)。
Claims (8)
1.具有下列化学结构的化合物及其可药用盐：
化合物(WZ00411)为：
N6-(1H-吲哚-5)-N2-(4-(4-氮甲基哌嗪苯基)-1H-吡唑[5，6-d]并嘧啶-4，6-二胺N4-(1H-indol-5-y1)-N6-[4-(4-methylpiperazin-1-y1)phenyl]-1H-pyrazolo[3，4-d]pyrimidine-4，6-diamine
谱图表征为：
1HNMR(600MHz，DMSO-d6)δ(ppm)：12.758(s，1H，-NH-)，11.079(s，1H，-NH-)，9.484(s，1H，-NH-)，8.786(s，1H，-NH-)，8.031(s，1H，-NH-)，7.629(d，J＝7.2Hz，2H，Ar-H)，7.391(d，J＝8.4Hz，3H，Ar-H)，7.352(s，1H，Ar-H)，6.83(d，J＝8.4Hz，2H，Ar-H)，6.415(s，1H，Ar-H)，3.135(s，4H，N-CH2-)，2.730(s，4H，N-CH2-)，2.412(s，3H，N-CH3).ESI-MSm/z：(M+H)+，calcdforC24H25N9：440.33。
2.权利要求上述化合物，其用于治疗肿瘤(如，肺癌、乳腺癌等)相关的疾病。
3.用于治疗肿瘤(如，肺癌、乳腺癌等)或与肿瘤相关的疾病的药物组合物，其包括权利要求1所述的化合物和药学上可接受的载体。
4.权利要求3所述的药物组合物，其被制成片剂、胶囊、口服液、注射剂、粉剂、膏剂或外用药液。
5.权利要求1中所述的化合物在制备用于治疗肿瘤(如，肺癌、乳腺癌等)或与肿瘤相关的疾病的药物中的应用。
6.用于治疗肿瘤(如，肺癌、乳腺癌等)或与肿瘤相关的疾病的方法，其包括向患者施用有效量的权利要求1中之任一所述的化合物。
7.权利要求3、4所述的化合物、药物组合物、权利要求5所述的应用或权利要求6所述的方法，其中肿瘤或与肿瘤相关的疾病是由表皮生长因子受体(EGFR)或T790M突变体(EGFRT790M)超出正常量表达和释放而导致的疾病。
8.权利要求1所述的化合物、权利要求3所述的药物组合物、权利要求6所述的应用或权利要求7所述的方法，其中肿瘤或与肿瘤相关的疾病选自肺癌、非小细胞肺癌、乳腺癌、骨肉瘤、皮肤癌、阴茎癌、膀胱癌、前列腺癌、宫颈癌、子宫肌瘤、胆管癌、胰腺癌、肝癌、胃癌、大肠癌、肾癌、鼻咽癌、食管癌、白血病、脑膜瘤、淋巴瘤及其并发症。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410635578.4A CN105566329B (zh) | 2014-11-07 | 2014-11-07 | 一种吡唑[5，6-d]并嘧啶类EGFR抑制剂及其抗肿瘤活性 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410635578.4A CN105566329B (zh) | 2014-11-07 | 2014-11-07 | 一种吡唑[5，6-d]并嘧啶类EGFR抑制剂及其抗肿瘤活性 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105566329A true CN105566329A (zh) | 2016-05-11 |
| CN105566329B CN105566329B (zh) | 2019-02-12 |
Family
ID=55877018
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410635578.4A Active CN105566329B (zh) | 2014-11-07 | 2014-11-07 | 一种吡唑[5，6-d]并嘧啶类EGFR抑制剂及其抗肿瘤活性 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105566329B (zh) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115141181A (zh) * | 2022-06-14 | 2022-10-04 | 温州医科大学 | 一种新型小分子化合物及其制备方法及用途 |
| CN115368366A (zh) * | 2022-08-02 | 2022-11-22 | 江苏省中医药研究院 | 嘧啶并吡唑类化合物及其应用 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008039359A2 (en) * | 2006-09-25 | 2008-04-03 | Janssen Pharmaceutica N.V. | Bicyclic pyrimidine kinase inhibitors |
| US20100144705A1 (en) * | 2008-12-05 | 2010-06-10 | Principia Biopharma Inc. | Egfr kinase knockdown via electrophilically enhanced inhibitors |
| CN103442568A (zh) * | 2010-10-08 | 2013-12-11 | Abbvie公司 | 呋喃并[3,2-d]嘧啶化合物 |
| CN103476767A (zh) * | 2011-02-09 | 2013-12-25 | 弗·哈夫曼-拉罗切有限公司 | 作为pi3激酶抑制剂的杂环化合物 |
| CN103797013A (zh) * | 2011-07-21 | 2014-05-14 | 埃斯蒂维实验室股份有限公司 | 吡唑并[3,4-d]嘧啶化合物、它们的制备及作为西格玛配体的用途 |
-
2014
- 2014-11-07 CN CN201410635578.4A patent/CN105566329B/zh active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008039359A2 (en) * | 2006-09-25 | 2008-04-03 | Janssen Pharmaceutica N.V. | Bicyclic pyrimidine kinase inhibitors |
| US20100144705A1 (en) * | 2008-12-05 | 2010-06-10 | Principia Biopharma Inc. | Egfr kinase knockdown via electrophilically enhanced inhibitors |
| CN103442568A (zh) * | 2010-10-08 | 2013-12-11 | Abbvie公司 | 呋喃并[3,2-d]嘧啶化合物 |
| CN103476767A (zh) * | 2011-02-09 | 2013-12-25 | 弗·哈夫曼-拉罗切有限公司 | 作为pi3激酶抑制剂的杂环化合物 |
| CN103797013A (zh) * | 2011-07-21 | 2014-05-14 | 埃斯蒂维实验室股份有限公司 | 吡唑并[3,4-d]嘧啶化合物、它们的制备及作为西格玛配体的用途 |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115141181A (zh) * | 2022-06-14 | 2022-10-04 | 温州医科大学 | 一种新型小分子化合物及其制备方法及用途 |
| CN115368366A (zh) * | 2022-08-02 | 2022-11-22 | 江苏省中医药研究院 | 嘧啶并吡唑类化合物及其应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105566329B (zh) | 2019-02-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Modi et al. | Vascular endothelial growth factor receptor (VEGFR-2)/KDR inhibitors: medicinal chemistry perspective | |
| CN113840606B (zh) | 给药kras抑制剂治疗癌症 | |
| JP7085985B2 (ja) | 悪性腫瘍治療用製剤及び組成物 | |
| ES2588197T3 (es) | Inhibidores de benzoxazol quinasa y métodos de uso | |
| EP4045047A1 (en) | Combination therapy of kras inhibitor and shp2 inhibitor for treatment of cancers | |
| Hou et al. | Design, synthesis, anti-tumor activity, and molecular modeling of quinazoline and pyrido [2, 3-d] pyrimidine derivatives targeting epidermal growth factor receptor | |
| JP7639010B2 (ja) | 化合物及びその使用 | |
| Guillard et al. | Molecular pharmacology of phosphatidylinositol 3-kinase inhibition in human glioma | |
| Dai et al. | Triazole-fused pyrimidines in target-based anticancer drug discovery | |
| CN101939006A (zh) | 磷酸肌醇3-激酶抑制剂化合物与化疗剂的联合以及使用方法 | |
| WO2022271966A1 (en) | Shp2 and cdk4/6 inhibitors combination therapies for the treatment of cancer | |
| Fan et al. | Discovery of Dioxino [2, 3-f] quinazoline derivative VEGFR-2 inhibitors exerting significant antipro-liferative activity in HUVECs and mice | |
| US10792277B2 (en) | Methods of treatment of fibrosis and cancers | |
| CN114901284A (zh) | 用细胞周期蛋白依赖性激酶7(cdk7)抑制剂治疗生物标志物鉴定的患者的癌症的方法 | |
| US20240058352A1 (en) | Combination therapies for the treatment of cancer | |
| CN105777716B (zh) | 一种用于靶向治疗癌症的egfr抑制剂及其制备方法与应用 | |
| CN105566329A (zh) | 一种吡唑[5，6-d]并嘧啶类EGFR抑制剂及其抗肿瘤活性 | |
| JP2007513967A (ja) | 変異レセプターチロシンキナーゼが駆動する細胞増殖性疾患の処置において使用するための組成物 | |
| Prasher et al. | Recent trends in rationally designed molecules as kinase inhibitors | |
| WO2021155100A1 (en) | Compounds and uses thereof | |
| JP2017520626A (ja) | 抗がん薬物とするアリールアミン置換のキノキサリン | |
| WO2022025880A1 (en) | Compounds and uses thereof | |
| Liu et al. | Discovery of 3-amide-pyrimidine-based derivatives as potential fms-like tyrosine receptor kinase 3 (FLT3) inhibitors for treating acute myelogenous leukemia | |
| Yang et al. | PP2 suppresses proliferation and migration of C6 Glioma and MDA-MB-231 cells by targeting both fibroblast growth factor receptor 1 and Src | |
| D Sriram | Structure-based Design and Synthesis of Novel Akt Inhibitors for Pre-clinical Evaluation in Lung Cancer Cell lines |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB03 | Change of inventor or designer information |
Inventor after: Liu Zhiguo Inventor after: Zhang Ying Inventor after: Zhang Qiaoqiao Inventor after: Ye Qingqing Inventor after: He Fan Inventor after: Pan Kailing Inventor after: Liang Guang Inventor after: Li Xiaokun Inventor before: Zhang Ying Inventor before: Zhang Qiaoqiao Inventor before: Ye Qingqing Inventor before: He Fan Inventor before: Pan Kailing Inventor before: Liu Zhiguo Inventor before: Liang Guang Inventor before: Li Xiaokun |
|
| CB03 | Change of inventor or designer information | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20210517 Address after: Room 2001, building a, Wenzhou Medical Equipment headquarters park, Xuefu North Road, Ouhai District, Wenzhou City, Zhejiang Province Patentee after: Yaogu (Wenzhou) Technology Development Co.,Ltd. Address before: Box 006, 38 Dongfang South Road, Ouhai Economic Development Zone, Wenzhou City, Zhejiang Province 325035 Patentee before: WENZHOU MEDICAL University |
|
| TR01 | Transfer of patent right |